News overview

Rene en Deborah site
Story
4 February 2021
‘The Wings of Science’ – a story of basic research with real life impact
What do Dutch researcher and Oncode Investigator Rene Bernards (NKI) and British columnist and podcaster Deborah James have in common? They are both on a mission to fight cancer. Bernards’ ultimate goal is to bring his research findings to the clinic and by that to impact people’s lives. James turned her own stage 4 bowel cancer diagnosis into a mission not only to fight the illness but also to change the conversation around it. The two met in 2018: as James was running out of treatment options, it was Bernards’ innovative therapy that came to her rescue.
Bianca-OliviaNita
Screenshot 2021 01 28 at 09 03 46
News
28 January 2021
Minister De Jonge visits COVID-19 test robot co-invented by Oncode Investigators Tanenbaum and De Laat
Last Wednesday, January 27th, Dutch Minister of health Hugo de Jonge visited the medical microbiology laboratories at PAMM to witness the newly installed STRIP-1 test robot which was installed end of the year. This test robot is capable of processing 20.000 COVID-19 qPCR-tests per 24 hours, making it unique in the world.
PeterThijssen
Schumacher Ton 01
News
26 January 2021
Oncode Investigator Ton Schumacher wins the prestigious Jeantet-Collen Prize for Translational Medicine
This award comes in recognition of his work developing technologies to study the role of the immune system in cancer progression, and for the improvement of cancer diagnosis and treatment. He will share the prize with french scientist Jerome Galon from the Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris.
Bianca-OliviaNita
NH20201125 016
News
16 December 2020
Biotech Wednesday – Spotlight on Cancer Treatments for the 21st Century
The second edition of Biotech Wednesday, an event organized by Oncode Institute in collaboration with HollandBio, switched locations, from Pakhuis de Zwijger to the online. What seemed at first a limitation turned out to be an opportunity. With a line-up of top speakers from both research and industry, and participants joining the event from 14 countries spread on three continents, this year’s digital edition of Biotech Wednesday was a success.
Bianca-OliviaNita
Quarterly Dec2020
News
4 December 2020
The December edition of Oncode’s digital magazine is here
Welcome to the last 2020 issue of Oncode’s digital magazine. As this unusual year comes to an end, December is the month to look back and forward.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Thumbnailt5Gr2Nz3
News
27 November 2020
A brand new video series about the Clinical Proof of Concept landscape
As part of the Clinical Proof Concept programme, the Oncode Exploratory Development Expert Support (OEDES) team has created a video series wherein they take you on an informative journey through the landscape of Clinical Proof of Concept. In this way, the OEDES team provides guidance and advice for Oncode Investigators and Researchers when it comes to translating our fundamental scientific insights into new diagnostics and therapeutic strategies.
Bianca-OliviaNita
Oncode Icons Square research strategy
News
26 November 2020
The platform that allows researchers to fully exploit available CRC studies is now available
The translation and validation of pre-clinical findings is often hampered and delayed due to unfamiliarity of basic researchers with trial cohorts providing valuable patient materials. But the new and updated CRC platform will contribute to changing that.
Bianca-OliviaNita
Virus
News
17 November 2020
Shedding light on viral infections
In times of a pandemic, there is not a day that goes by without news about viruses. Still, the newest paper from the lab of Oncode Investigator Marvin Tanenbaum, performed in collaboration with the group of Frank van Kuppeveld (University Utrecht), is something special.
Bianca-OliviaNita
Oncode Icons Square 22
News
27 October 2020
First finalized Oncode Clinical Proof of Concept (CPoC) project
We are happy to announce that our first Oncode CPoC study - a collaboration between Oncode Investigator Jean Paul Medema (Amsterdam UMC) and clinician Henk Verheul (Radboud UMC) titled Pulsatile high dose Sunitinib as a specific drug for (a subset of) metastatic mesenchymal CRCs - is now finalized.
Bianca-OliviaNita
Oncode Icons Square research strategy copy
News
12 October 2020
New CPoC grant awarded: researchers and clinicians team up for study on gastroenteropancreatic neuroendocrine tumors (GEPNETs)
Oncode Institute keeps investing in bringing insights from basic science into clinical practice. With the 12th grant awarded within the CPoC programme, Oncode Investigator Roland Kanaar together with Oncode researcher Julie Nonnekens (both Erasmus MC) will team up with a group of clinicians, a physicist and pharmacist for a project focused on gastroenteropancreatic neuroendocrine tumors (GEPNETs).
Bianca-OliviaNita
Oncode about icon copy 4
News
29 September 2020
Oncode Facilities & Technologies will add value to your research
The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Investing in new technologies and facilities - which are available to all Oncode researchers - is one of the ways that Oncode wants to contribute to breakthroughs in cancer research. In this interview Jacqueline Staring, Programme Manager at Oncode Institute, discusses the facilities and technologies that are available for the Oncode research community and how they will support and accelerate oncology research.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Icon bridgefund
News
29 September 2020
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics
Oncode Institute is proud to announce that Immagene B.V. launched this month as a private biotech company, focused on developing next-generation precision immuno-oncology therapeutics. The company announced its launch following a successful fundraise from Oncode Bridge Fund, Swanbridge Capital, and Innovatiefonds Noord Holland.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.